Skip to content

The effect of stereotactic radiotherapy on cognitive functioning and quality of life of patients with one to three brain metastases: a prospective study

The effect of stereotactic radiotherapy on cognitive functioning and quality of life of patients with one to three brain metastases: a prospective study - Cognition and quality of life after SRT for brain metastases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32515
Enrollment
50
Registered
2008-12-02
Start date
2009-01-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain metastases

Interventions

None listed

Sponsors

Medisch Centrum Haaglanden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patient with * 3 newly diagnosed brain metastases, 2. Adult (* 18 years), 3. Patient will be treated with SRT, 4. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patient has had any treatment (i.e. surgery, biopsy, WBRT and/or SRT) for his brain metastatic disease, 2. Patient will be treated with both WBRT and a SRT boost, 3. Patient has insufficient mastery of the Dutch language, 4. patient has other neurological or psychiatric conditions which could interfere with the results, 5. according to the treating physician, patient is (expected to be) unable to participate in the follow up period, because of serious physical or mental conditions (i.e. a KPS score below 70),

Design outcomes

Primary

MeasureTime frame
Indicators of cognitive functioning, fatigue, quality of life and radiological features will be assessed as primary outcomes at baseline (before SRT), one month after completion of SRT, and again three months and six months after completion of SRT.

Secondary

MeasureTime frame
Neurological functioning and self care (in daily life)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)